Fracture Risk With Thiazolidinediones

Study Type:	Observational
Study Design:	Observational Model: Case-Control; Time Perspective: Retrospective
Conditions:	Fractures, Bone; Type II Diabetes
Interventions:	Drug: TZD only (RSG or PIO or troglitazone); Drug: TZD + spironolactone; Drug: TZD + amiloride

  Participant Flow

  Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

Description

TZD 6-month Cohort (Including TZD 12-month Cohort)

The study population consisted of type 2 diabetes patients 18-65 years old exposed to thiazolidinedione (TZD). To be eligible for the study, a subject must have had at least one International Classification of Disease (ICD)-9 code for type 2 diabetes and have at least 6 months of exposure to TZD (rosiglitazone [RSG], pioglitazone [PIO], or troglitazone) during their follow-up time available in the database. A subset of patients were followed for at least 12 months (Outcome measure results for this subset also presented). Dose information was not collected.

Participant Flow:   Overall Study

	TZD 6-month Cohort (Including TZD 12-month Cohort)
STARTED	98483
COMPLETED	98483
NOT COMPLETED	0

  Baseline Characteristics

  Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

Description

TZD 6-month Cohort (Including TZD 12-month Cohort)

The study population consisted of type 2 diabetes patients 18-65 years old exposed to thiazolidinedione (TZD). To be eligible for the study, a subject must have had at least one International Classification of Disease (ICD)-9 code for type 2 diabetes and have at least 6 months of exposure to TZD (rosiglitazone [RSG], pioglitazone [PIO], or troglitazone) during their follow-up time available in the database. A subset of patients were followed for at least 12 months (Outcome measure results for this subset also presented). Dose information was not collected.

Baseline Measures

	TZD 6-month Cohort (Including TZD 12-month Cohort)
Overall Participants Analyzed; [Units: Participants]	98483
Age; [Units: Years]; Mean (Standard Deviation)	52.2 (8.33)
Sex: Female, Male; [Units: Participants]; Count of Participants
Female	37738 38.3%
Male	60745 61.7%

  Outcome Measures

  Show All Outcome Measures

1. Primary:

Number of Low Impact Fractures in Males and Females After 6 Months of Exposure to TZD [ Time Frame: From the earliest date of first TZD prescription to the fracture diagnosis date (Cases) or the end of follow-up in the database (Controls) between January 1, 1997 and December 31, 2008 ]

  Show Outcome Measure 1

2. Primary:

Number of Low Impact Fractures in Males and Females After 12 Months of Exposure to TZD [ Time Frame: From the earliest date of first TZD prescription to the fracture diagnosis date (Cases) or the end of follow-up in the database (Controls) between January 1, 1997 to December 31, 2008 ]

  Show Outcome Measure 2

3. Secondary:

Number of Fractures of the Hand, Foot, Upper Arm, and Wrist in Males and Females After 6 Months of Exposure to TZD [ Time Frame: From the earliest date of first TZD prescription to the fracture diagnosis date (Cases) or the end of follow-up in the database (Controls) between January 1, 1997 to December 31, 2008 ]

  Show Outcome Measure 3

4. Secondary:

Number of Fractures of the Hand, Foot, Upper Arm, and Wrist in Males and Females After 12 Months of Exposure to TZD [ Time Frame: From the earliest date of first TZD prescription to the fracture diagnosis date (Cases) or the end of follow-up in the database (Controls) between January 1, 1997 to December 31, 2008 ]

  Show Outcome Measure 4

5. Secondary:

Number of Hip Fractures Combined in Males and Females After 6 Months of Exposure to TZD [ Time Frame: From the earliest date of first TZD prescription to the fracture diagnosis date (Cases) or the end of follow-up in the database (Controls) between January 1, 1997 to December 31, 2008 ]

  Show Outcome Measure 5

6. Secondary:

Number of Hip Fractures Combined in Males and Females After 12 Months of Exposure to TZD [ Time Frame: From the earliest date of first TZD prescription to the fracture diagnosis date (Cases) or the end of follow-up in the database (Controls) between January 1, 1997 to December 31, 2008 ]

  Show Outcome Measure 6

  Serious Adverse Events

  Show Serious Adverse Events

  Other Adverse Events

  Show Other Adverse Events

  Limitations and Caveats

  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

  Hide More Information

Certain Agreements:  

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is: The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo. The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.; Restriction Description: GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.

Results Point of Contact:  

Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343

Responsible Party:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT01055223 History of Changes
Other Study ID Numbers:	113332
First Submitted:	January 21, 2010
First Posted:	January 25, 2010
Results First Submitted:	December 16, 2010
Results First Posted:	April 18, 2011
Last Update Posted:	May 30, 2017